April 2018 Cancer Epidemiology Matters E-News

Cancer Epidemiology Matters E-News

April 2018

NIH Stimulates Research Focused on the Role of Early-Life Factors in Cancer Development

Emerging evidence suggests that exposures to risk factors early in life, in utero through adolescence and young adulthood, may have significant consequences for cancer development later in life. Thus, it is necessary to improve the understanding of these associations and their underlying biological processes in order to develop effective prevention interventions.

Most cancer research in human populations has focused on exposures occurring in middle age and beyond, and thus may miss exposures occurring at younger ages during critical windows of susceptibility. For example, recent findings published in Cell from the Tracking Renal Cell Carcinoma Evolution Through Therapy study (TRACERxRenal) indicate that genetic changes relevant to early development of clear cell renal cell carcinoma may occur in childhood or adolescence, indicating a long latency period of 30 to 50 years between exposure and cancer diagnosis.

Ongoing efforts in the Breast Cancer and the Environment Research ProgramExternal Web Site Policy examine the associations between environmental exposures during critical periods in a woman’s lifespan and breast cancer risk. Another effort, the Environmental influences on Child Health Outcomes (ECHO) program, while not focused on cancer, supports investigations of early-life exposures on health and development.

The Epidemiology and Genomics Research Program (EGRP) in the National Cancer Institute’s (NCI) Division of Cancer Control and Population Sciences (DCCPS) recently published several funding opportunity announcements (FOAs) to stimulate research in early-life exposures and cancer:

*Note: Clinical trials not allowed

Investigators with questions about these FOAs should contact Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch, EGRP.



Apply by July 1 for Supplemental Funds to Enhance Cancer Epidemiologic Data Sharing

Investigators with eligible NCI grant awards are encouraged to apply for an administrative supplement to assist with the preparation and deposition of individual-level data from cancer epidemiology studies into an appropriate NIH- or NCI-supported controlled-access database. Sharing of research data will increase opportunities for collaboration and accelerate scientific discoveries related to cancer etiology, risk factors, and cancer survivorship.

To help investigators comply with the NIH Data Sharing Policy and Genomic Data Sharing Policy, NCI and NIH support a number of data repositories to help facilitate efficient data sharing, including the database of Genotypes and Phenotypes (dbGaP) and the Cancer Epidemiology Data Repository (CEDR).

Investigators with P01, U19, R01, U01, and UM1 awards may submit applications requesting up to $150,000 in total costs to assist with activities including data cleaning, creating data dictionaries and dataset documentation, and submitting data to an NIH or NCI repository. Applications may pertain to data sharing from all types of observational cancer epidemiology studies, as well as partial datasets that complement or critically update previously shared data. It is important to note that data sharing activities for this supplement must go beyond that which are detailed in the resource sharing plan of the parent grant.

The funding opportunity announcement (FOA), PA-18-748, was published in the NIH Guide for Grants and Contracts in April 2018 and applications may be submitted between June 1 and July 1, 2018. Please note that clinical trials are not allowed.

Investigators with questions about this FOA should contact Danielle Daee, Ph.D., Program Director, Genomic Epidemiology Branch, EGRP.

Funding Opportunities

  • Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01, R21, Clinical Trial Optional)
  • Improving the Reach and Quality of Cancer Care in Rural Populations (R01, Clinical Trial Required)
  • Research on the Health of Transgender and Gender Nonconforming Populations (R01, R21, Clinical Trial Optional)
  • Revision Applications to National Cancer Institute's (NCI) Supported Awards to Include Research on the NCI's Provocative Questions (R01, U01, P01, P50, Clinical Trial Optional)

Grantsmanship Notices

  • Career Award (K) Policy Update: Temporary Adjustments to Percent Effort or Part-Time Institutional Appointment (NOT-OD-18-156)
  • Career Award (K) Policy Update: Concurrent Support from a Mentored K Award and a Research Grant (NOT-OD-18-157)

Return to Top